RU2015134423A - Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств - Google Patents
Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств Download PDFInfo
- Publication number
- RU2015134423A RU2015134423A RU2015134423A RU2015134423A RU2015134423A RU 2015134423 A RU2015134423 A RU 2015134423A RU 2015134423 A RU2015134423 A RU 2015134423A RU 2015134423 A RU2015134423 A RU 2015134423A RU 2015134423 A RU2015134423 A RU 2015134423A
- Authority
- RU
- Russia
- Prior art keywords
- active agent
- additional active
- paragraphs
- combination
- specified
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title claims 5
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 title claims 4
- 229960005127 montelukast Drugs 0.000 title claims 4
- 238000000034 method Methods 0.000 claims 25
- 239000013543 active substance Substances 0.000 claims 9
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 claims 3
- 239000000654 additive Substances 0.000 claims 3
- 230000000996 additive effect Effects 0.000 claims 3
- 239000003862 glucocorticoid Substances 0.000 claims 3
- 229960001508 levocetirizine Drugs 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 230000002584 immunomodulator Effects 0.000 claims 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims 2
- 230000001861 immunosuppressant effect Effects 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical group C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 claims 1
- 108010029961 Filgrastim Proteins 0.000 claims 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 229930003268 Vitamin C Natural products 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 229960000860 dapsone Drugs 0.000 claims 1
- 229960004177 filgrastim Drugs 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical group [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical group C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 150000003431 steroids Chemical group 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 235000019154 vitamin C Nutrition 0.000 claims 1
- 239000011718 vitamin C Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (25)
1. Способ лечения аутоиммунного расстройства у нуждающегося в этом пациента, включающий введение пациенту эффективного количества комбинации левоцетиризина и монтелукаста.
2. Способ лечения симптома аутоиммунного расстройства у нуждающегося в этом пациента, включающий введение пациенту эффективного количества комбинации левоцетиризина и монтелукаста.
3. Способ по любому из пп. 1 и 2, отличающийся тем, что указанное аутоиммунное расстройство представляет собой идиопатическую тромбоцитопеническую пурпуру.
4. Способ по любому из пп. 1 и 2, отличающийся тем, что указанное аутоиммунное расстройство представляет собой аутоиммунную нейтропению.
5. Способ по любому из пп. 1 и 2, отличающийся тем, что указанную комбинацию вводят при возникновении симптомов.
6. Способ по любому из пп. 1 и 2, отличающийся тем, что указанную комбинацию вводят последовательным образом.
7. Способ по любому из пп. 1 и 2, отличающийся тем, что указанную комбинацию вводят, по существу, одновременно.
8. Способ по любому из пп. 1 и 2, дополнительно включающий введение дополнительного активного агента.
9. Способ по п. 8, отличающийся тем, что указанный дополнительный активный агент представляет собой стероид.
10. Способ по п. 8, отличающийся тем, что указанный дополнительный активный агент представляет собой глюкокортикоид.
11. Способ по п. 9, отличающийся тем, что указанный глюкокортикоид представляет собой преднизон.
12. Способ по п. 9, отличающийся тем, что указанный глюкокортикоид представляет собой метилпреднизолон.
13. Способ по п. 8, отличающийся тем, что указанный дополнительный активный агент представляет собой иммунодепрессант.
14. Способ по п. 13, отличающийся тем, что указанный иммунодепрессант представляет собой метотрексат.
15. Способ по п. 8, отличающийся тем, что указанный дополнительный активный агент представляет собой добавку.
16. Способ по п. 15, отличающийся тем, что указанная добавка представляет собой глюконат железа.
17. Способ по п. 15, отличающийся тем, что указанная добавка представляет собой витамин С.
18. Способ по п. 8, отличающийся тем, что указанный дополнительный активный агент является антибактериальным.
19. Способ по п. 18, отличающийся тем, что указанный дополнительный активный агент представляет собой дапсон.
20. Способ по п. 8, отличающийся тем, что указанный дополнительный активный агент представляет собой белок.
21. Способ по п. 20, отличающийся тем, что указанный белок представляет собой филграстим.
22. Способ по п. 8, отличающийся тем, что указанный дополнительный активный агент представляет собой иммуномодулятор.
23. Способ по п. 22, отличающийся тем, что указанный иммуномодулятор представляет собой леналидомид.
24. Способ по любому из пп. 1 и 2, отличающийся тем, что указанную комбинацию вводят пациенту одним или более путей из группы, состоящей из энтерального, внутривенного, внутрибрюшинного, ингаляционного, внутримышечного, подкожного и перорального путей.
25. Способ по любому из пп. 1 и 2, отличающийся тем, что левоцетиризин и монтелукаст вводят одинаковым путем.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780420P | 2013-03-13 | 2013-03-13 | |
| US61/780,420 | 2013-03-13 | ||
| PCT/US2014/021784 WO2014164299A1 (en) | 2013-03-13 | 2014-03-07 | Use of levocetirizine and montelukast in the treatment of autoimmune disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015134423A true RU2015134423A (ru) | 2017-04-26 |
Family
ID=51658850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015134423A RU2015134423A (ru) | 2013-03-13 | 2014-03-07 | Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9669026B2 (ru) |
| EP (2) | EP3300734B1 (ru) |
| JP (1) | JP6441888B2 (ru) |
| KR (1) | KR20150138849A (ru) |
| CN (1) | CN105228700A (ru) |
| AU (1) | AU2014249456B2 (ru) |
| CA (1) | CA2901421A1 (ru) |
| ES (2) | ES2745041T3 (ru) |
| MX (1) | MX370953B (ru) |
| RU (1) | RU2015134423A (ru) |
| WO (1) | WO2014164299A1 (ru) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9044479B2 (en) | 2010-06-16 | 2015-06-02 | Bruce Chandler May | Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation |
| AU2014249456B2 (en) | 2013-03-13 | 2018-08-09 | IRR, Inc. | Use of levocetirizine and montelukast in the treatment of autoimmune disorders |
| EP3308835B1 (en) | 2013-03-13 | 2020-01-01 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of traumatic injury |
| CN105263579B (zh) | 2013-03-13 | 2020-01-10 | 炎症反应研究公司 | 左西替利嗪和孟鲁司特在治疗血管炎中的用途 |
| JP2017526728A (ja) | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
| DK3209655T3 (da) | 2014-10-24 | 2020-09-28 | Landos Biopharma Inc | Lanthioninsyntease C-lignende 2-baserede Therapeutica |
| EP3463324A4 (en) * | 2016-06-03 | 2020-01-29 | Irr, Inc. | LEVOCETTIRIZINE AND MONTELUKAST IN THE TREATMENT OF MEDIATED CONDITIONS OF MEDIA BY EXPOSURE TO RADIATION |
| US11648252B2 (en) | 2018-04-27 | 2023-05-16 | Gf Service S.R.L. | Methotrexate for use as a medicament |
| CN109675637A (zh) * | 2018-12-19 | 2019-04-26 | 天津理工大学 | 一种亚铁盐修饰的α-三氧化二铁薄膜的制备方法 |
| JP7430852B2 (ja) | 2019-12-20 | 2024-02-14 | エヌイミューン バイオファーマ インコーポレイテッド | ランチオニンｃ様タンパク質２リガンド、それを用いて調製される細胞、およびそれを使用する療法 |
| US11918570B2 (en) | 2020-04-13 | 2024-03-05 | The Research Foundation For The State University Of New York | Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition |
| EP4153178A4 (en) * | 2020-05-19 | 2024-06-05 | Irr, Inc. | LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF SEPSIS AND SYMPTOMS THEREOF |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4801612A (en) | 1986-07-03 | 1989-01-31 | Regents Of The University Of California | Method of inhibiting inflammatory response |
| US5211958A (en) | 1987-11-30 | 1993-05-18 | Gist-Brocades, N.V. | Pharmaceutical composition and process for its preparation |
| US5147637A (en) | 1988-06-07 | 1992-09-15 | The Rockefeller University | Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma |
| JPH07503629A (ja) | 1991-11-14 | 1995-04-20 | アライアンス ファーマシューティカル コーポレイション | フルオロカーボンを用いた部分的液体呼吸法および装置 |
| JPH09510952A (ja) * | 1993-10-06 | 1997-11-04 | ザ ケネディー インスティチュート オブ リューマトロジー | 自己免疫疾患および炎症性疾患の治療 |
| JP2001511134A (ja) * | 1997-01-24 | 2001-08-07 | オートイミューン インク | メトトレキサートと組合せる耐性化を用いる自己免疫疾患の治療 |
| WO1999032125A1 (en) | 1997-12-23 | 1999-07-01 | Schering Corporation | Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine |
| AU2470299A (en) | 1998-01-27 | 1999-08-09 | Nutramax Laboratories, Inc. | Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances |
| US6384038B1 (en) | 1998-04-14 | 2002-05-07 | Sepracor Inc. | Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
| US7186555B1 (en) | 1999-04-13 | 2007-03-06 | The Feinstein Institute For Medical Research | Prevention of brain damage in stroke |
| US20020006961A1 (en) | 1999-05-14 | 2002-01-17 | Katz Stanley E. | Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response |
| DE10007203A1 (de) | 2000-02-17 | 2001-08-23 | Asta Medica Ag | Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis |
| US20010051624A1 (en) | 2000-04-12 | 2001-12-13 | Jones Thomas R. | Method and compositions for the treatment of allergic conditions using PGD2 receptor antagonists |
| US20020052312A1 (en) | 2000-05-30 | 2002-05-02 | Reiss Theodore F. | Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists |
| NZ524121A (en) | 2000-07-28 | 2005-09-30 | Immupharm Aps | Compounds for treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
| US7718198B2 (en) * | 2001-06-20 | 2010-05-18 | Metaproteomics, Llc | Treatment modalities for autoimmune diseases |
| RO122476B1 (ro) | 2001-06-28 | 2009-07-30 | Ucb S.A. | Tabletă conţinând cetirizină şi pseudoefedrină |
| EP1471907B1 (en) * | 2001-06-29 | 2008-07-16 | AB Science | Use of c-kit inhibitors for treating autoimmune diseases |
| HU224941B1 (en) | 2001-08-10 | 2006-04-28 | Bgi Innovacios Kft | Phototerapy apparatus |
| AU2003264859A1 (en) | 2001-12-21 | 2003-12-19 | Sampad Bhattacharya | Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor |
| DE50312523D1 (de) | 2002-05-24 | 2010-04-29 | Carl-Fr Coester | Pharmazeutische wirkstoffkombination sowie deren verwendung |
| US7291331B1 (en) | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
| CA2518409A1 (en) | 2003-03-12 | 2004-09-23 | John P. Mullally | Composition and method for treating inflammations by reducing c-reactive protein |
| US7666417B2 (en) * | 2003-04-22 | 2010-02-23 | Fred Hutchinson Cancer Research Center | Methods and compositions for treating autoimmune diseases or conditions |
| US20060263350A1 (en) | 2003-09-26 | 2006-11-23 | Fairfield Clinical Trials Llc | Combination antihistamine medication |
| WO2006010283A1 (en) | 2004-07-28 | 2006-02-02 | Universität Zürich | Prevention and treatment of thrombus formation |
| ZA200702335B (en) | 2004-10-05 | 2009-05-27 | Genentech Inc | Method for treating vasculitis |
| US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US20070244128A1 (en) | 2005-11-04 | 2007-10-18 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| WO2007056510A2 (en) | 2005-11-09 | 2007-05-18 | The Children's Hospital Of Philadelphia | Chloride transport upregulation for the treatment of traumatic brain injury |
| JP5107933B2 (ja) * | 2005-12-21 | 2012-12-26 | メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 炎症性疾患の治療に使用する、抗コリン作用薬類、β２−アドレナリン受容体のアゴニスト類、抗ロイコトリエン（ロイコトリエン受容体のアンタゴニスト）類、グルココルチコイド類および／またはＰＤＥ４阻害剤類の新規配合薬 |
| US7589076B2 (en) | 2006-05-18 | 2009-09-15 | Pgx Health, Llc | Substituted aryl piperidinylalkynyladenosines as A2AR agonists |
| EP2559434A3 (en) | 2007-02-12 | 2013-05-29 | Mike Nicolaou | Treatment of COPD using a histidine decarboxylase inhibitor sole or combined with an anti-H1 drug or with a leucotriene receptor antagonist |
| EP2129683A4 (en) | 2007-02-26 | 2011-01-05 | Ironwood Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR TREATMENT OF HEART FAILURE AND OTHER DISORDERS |
| WO2009022327A2 (en) | 2007-08-15 | 2009-02-19 | Chemagis Ltd. | Novel process for preparing highly pure levocetirizine and salts thereof |
| US20100305080A1 (en) | 2007-10-25 | 2010-12-02 | O'shea Paul | Novel Crystalline Salts of Montelukast |
| US20090227018A1 (en) | 2007-10-25 | 2009-09-10 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
| CA2703672A1 (en) | 2007-10-25 | 2009-04-30 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
| PL2403845T3 (pl) * | 2009-03-02 | 2014-09-30 | Generics Uk Ltd | Ulepszony sposób |
| WO2010107404A1 (en) | 2009-03-16 | 2010-09-23 | Mahmut Bilgic | Stable pharmaceutical combinations |
| US8263581B2 (en) | 2009-07-03 | 2012-09-11 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| BR112012018913A2 (pt) | 2010-01-28 | 2017-06-20 | Merck Sharp & Dohme | "composição farmacêutica, e, uso da composição" |
| US9044479B2 (en) | 2010-06-16 | 2015-06-02 | Bruce Chandler May | Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation |
| JP2013535456A (ja) | 2010-07-28 | 2013-09-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器系及び炎症性疾患の治療用医薬組成物 |
| TR201009398A2 (tr) | 2010-11-11 | 2012-05-21 | Bi̇lgi̇ç Mahmut | Fiziksel özellikleri geliştirilmiş tablet formülasyonları |
| EP2658538A2 (en) | 2010-12-30 | 2013-11-06 | M.D. Ziv Harish | Preparations for topical prevention and/or treatment of oral allergic symptoms due to oral contact with fruits and/or vegetables |
| US20130030009A1 (en) | 2010-12-30 | 2013-01-31 | Ziv Harish | Method for the treatment and/or prevention of oral allergic symptions of the lips due to oral contact with a food allergen |
| MX2013011888A (es) | 2011-04-13 | 2014-02-27 | Revalesio Corp | Composiciones y metodos para inhibir y/o modular las celulas-t efectoras involucradas en la enfermedad neurodegenerativa inflamatoria. |
| EP2520292A1 (en) | 2011-05-06 | 2012-11-07 | Helmholtz-Zentrum für Infektionsforschung GmbH | Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders |
| KR20130009553A (ko) | 2011-07-15 | 2013-01-23 | 한미약품 주식회사 | 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제 |
| MX336224B (es) * | 2011-07-26 | 2016-01-12 | Boehringer Ingelheim Int | Quinolinas sustituidas y su uso como medicamentos. |
| CN102895661A (zh) * | 2011-07-28 | 2013-01-30 | 中国科学院上海药物研究所 | 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途 |
| US9730921B2 (en) | 2012-03-27 | 2017-08-15 | Duke University | Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage |
| CN103505731A (zh) | 2012-06-15 | 2014-01-15 | 中国药科大学 | 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途 |
| US20150322049A1 (en) | 2012-12-13 | 2015-11-12 | Ludwig Aigner | Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease |
| MX2015011775A (es) | 2013-03-13 | 2015-12-01 | Inflammatory Response Res Inc | Uso de levocetirizina y montelukast en el tratamiento de anafilaxis. |
| EP3308835B1 (en) | 2013-03-13 | 2020-01-01 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of traumatic injury |
| CN105263579B (zh) | 2013-03-13 | 2020-01-10 | 炎症反应研究公司 | 左西替利嗪和孟鲁司特在治疗血管炎中的用途 |
| AU2014249456B2 (en) | 2013-03-13 | 2018-08-09 | IRR, Inc. | Use of levocetirizine and montelukast in the treatment of autoimmune disorders |
| JP2017526728A (ja) | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
| EP3463324A4 (en) | 2016-06-03 | 2020-01-29 | Irr, Inc. | LEVOCETTIRIZINE AND MONTELUKAST IN THE TREATMENT OF MEDIATED CONDITIONS OF MEDIA BY EXPOSURE TO RADIATION |
-
2014
- 2014-03-07 AU AU2014249456A patent/AU2014249456B2/en active Active
- 2014-03-07 EP EP17195345.8A patent/EP3300734B1/en active Active
- 2014-03-07 MX MX2015012322A patent/MX370953B/es active IP Right Grant
- 2014-03-07 JP JP2016500849A patent/JP6441888B2/ja active Active
- 2014-03-07 RU RU2015134423A patent/RU2015134423A/ru unknown
- 2014-03-07 CN CN201480013712.5A patent/CN105228700A/zh active Pending
- 2014-03-07 EP EP14778050.6A patent/EP2969010B1/en active Active
- 2014-03-07 ES ES17195345T patent/ES2745041T3/es active Active
- 2014-03-07 CA CA2901421A patent/CA2901421A1/en not_active Abandoned
- 2014-03-07 WO PCT/US2014/021784 patent/WO2014164299A1/en active Application Filing
- 2014-03-07 KR KR1020157027766A patent/KR20150138849A/ko not_active Application Discontinuation
- 2014-03-07 ES ES14778050.6T patent/ES2654093T3/es active Active
-
2015
- 2015-08-20 US US14/831,339 patent/US9669026B2/en active Active
-
2017
- 2017-05-02 US US15/584,795 patent/US10201537B2/en active Active
-
2018
- 2018-12-18 US US16/224,129 patent/US11344545B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014164299A1 (en) | 2014-10-09 |
| EP2969010A1 (en) | 2016-01-20 |
| AU2014249456A1 (en) | 2015-08-27 |
| EP2969010A4 (en) | 2016-10-05 |
| EP3300734B1 (en) | 2019-08-14 |
| US20170296534A1 (en) | 2017-10-19 |
| ES2654093T3 (es) | 2018-02-12 |
| US10201537B2 (en) | 2019-02-12 |
| AU2014249456B2 (en) | 2018-08-09 |
| ES2745041T3 (es) | 2020-02-27 |
| US9669026B2 (en) | 2017-06-06 |
| EP3300734A2 (en) | 2018-04-04 |
| CA2901421A1 (en) | 2014-10-09 |
| US11344545B2 (en) | 2022-05-31 |
| JP6441888B2 (ja) | 2018-12-19 |
| EP2969010B1 (en) | 2017-10-11 |
| JP2016512263A (ja) | 2016-04-25 |
| US20150352103A1 (en) | 2015-12-10 |
| US20190201392A1 (en) | 2019-07-04 |
| CN105228700A (zh) | 2016-01-06 |
| EP3300734A3 (en) | 2018-04-18 |
| KR20150138849A (ko) | 2015-12-10 |
| MX2015012322A (es) | 2015-12-16 |
| MX370953B (es) | 2020-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015134423A (ru) | Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств | |
| PH12015502773A1 (en) | Methods for treating or preventing opthalmological conditions | |
| HRP20200009T1 (hr) | Angiotenzin ii u kombinaciji za liječenje hipotenzije | |
| NZ774222A (en) | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof | |
| MX2016000384A (es) | Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos. | |
| EA201691375A1 (ru) | (2s)-n-[(1s)-1-циано-2-фенилэтил]-1,4-оксазепан-2-карбоксамиды в качестве ингибиторов дипептидилпептидазы i | |
| MY189333A (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| EA201591751A1 (ru) | Трипептидные эпоксикетонные ингибиторы протеазы | |
| EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| EA201990428A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| RU2015134422A (ru) | Применение левоцитиризина и монтелукаста при лечении васкулита | |
| EA201501054A1 (ru) | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы | |
| EA201891514A1 (ru) | Комбинированная терапия ингибитором бромодомена и экстратерминального белка | |
| RU2015134421A (ru) | Применение левоцетиризина и монтелукаста при лечении травматических повреждений | |
| EA201991387A1 (ru) | ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ | |
| MX2019005435A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| MX366134B (es) | Angiotensina en el tratamiento de condiciones cerebrales. | |
| JP2016517421A5 (ru) | ||
| JP2017503014A5 (ru) | ||
| FI3383385T4 (fi) | Melflufeeniannoskuureja syöpään | |
| MX2019009586A (es) | Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal. | |
| WO2016029136A8 (en) | 3-amidobenzamides and uses thereof for increasing cellular levels of a3g |